Delivery of self-amplifying mRNA vaccines by cationic lipid nanoparticles: The impact of cationic lipid selection

Wolff, 1990, Direct gene transfer into mouse muscle in vivo, Science, 247, 1465, 10.1126/science.1690918 Tang, 1992, Genetic immunization is a simple method for eliciting an immune response, Nature, 356, 152, 10.1038/356152a0 Maruggi, 2019, mRNA as a transformative technology for vaccine development to control infectious diseases, Mol. Ther., 27, 757, 10.1016/j.ymthe.2019.01.020 Geall, 2012, Nonviral delivery of self-amplifying RNA vaccines, Proc Natl Acad Sci U S A, 109, 14604, 10.1073/pnas.1209367109 Vogel, 2018, Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses, Mol. Ther., 26, 446, 10.1016/j.ymthe.2017.11.017 Probst, 2006, Characterization of the ribonuclease activity on the skin surface, Genetic vaccines and therapy, 4, 10.1186/1479-0556-4-4 Brito, 2014, A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines, Mol. Ther., 22, 2118, 10.1038/mt.2014.133 Demoulins, 2016, Polyethylenimine-based polyplex delivery of self-replicating RNA vaccines, Nanomedicine, 12, 711, 10.1016/j.nano.2015.11.001 Goswami, 2019 Jayaraman, 2012, Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, Angew. Chem. Int. Ed. Engl., 51, 8529, 10.1002/anie.201203263 Richner, 2017, Modified mRNA vaccines protect against zika virus infection, Cell, 168, 1114, 10.1016/j.cell.2017.02.017 Hekele, 2013, Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice, Emerging Microbes Infect., 2, 1, 10.1038/emi.2013.54 Hassett, 2019, Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines, Mol. Ther. Nucleic Acids, 15, 1, 10.1016/j.omtn.2019.01.013 Kauffman, 2015, Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs, Nano Lett., 15, 7300, 10.1021/acs.nanolett.5b02497 Henriksen-Lacey, 2011, Mol. Pharm., 8, 153, 10.1021/mp100208f McNeil, 2010, Lipoplexes formulation and optimisation: in vitro transfection studies reveal no correlation with in vivo vaccination studies, Curr. Drug Deliv., 7, 175, 10.2174/156720110791011774 Patel, 2019, Lipid nanoparticles for delivery of messenger RNA to the back of the eye, J. Control. Release, 303, 91, 10.1016/j.jconrel.2019.04.015 Ertl, 2009, Novel vaccines to human rabies, PLoS Negl.Trop. Dis., 3, 10.1371/journal.pntd.0000515 Lou, 2019, A novel microfluidic-based approach to formulate size-tuneable large unilamellar cationic liposomes: Formulation, cellular uptake and biodistribution investigations, Eur. J. Pharm. Biopharm., 143, 51, 10.1016/j.ejpb.2019.08.013 Feyssaguet, 2007, Vaccine, 25, 2244, 10.1016/j.vaccine.2006.12.012 Gallorini, 2014, Sublingual immunization with a subunit influenza vaccine elicits comparable systemic immune response as intramuscular immunization, but also induces local IgA and TH17 responses, Vaccine, 32, 2382, 10.1016/j.vaccine.2013.12.043 Chatzikleanthous, 2020, Design of a novel vaccine nanotechnology-based delivery system comprising CpGODN-protein conjugate anchored to liposomes, J. Control. Release, 10.1016/j.jconrel.2020.04.001 Cullis, 2017, Lipid nanoparticle systems for enabling gene therapies, Mol. Ther., 25, 1467, 10.1016/j.ymthe.2017.03.013 Xiang, 1995, Immune effector mechanisms required for protection to rabies virus, Virology, 214, 398, 10.1006/viro.1995.0049 Wiktor, 1978, Cell-mediated immunity and postexposure protection from rabies by inactivated vaccines of tissue culture origin, Dev. Biol. Stand., 40, 255 Schnee, 2016, An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs, PLoS Negl.Trop. Dis., 10, 10.1371/journal.pntd.0004746 Henriksen-Lacey, 2010, Liposomes based on dimethyldioctadecylammonium promote a depot effect and enhance immunogenicity of soluble antigen, J. Control. Release, 142, 180, 10.1016/j.jconrel.2009.10.022 Kaur, 2012, Manipulation of the surface pegylation in combination with reduced vesicle size of cationic liposomal adjuvants modifies their clearance kinetics from the injection site, and the rate and type of T cell response, J. Controlled Release : Off. J. Controlled Release Soc., 164, 331, 10.1016/j.jconrel.2012.07.012 Regelin, 2000, Biophysical and lipofection studies of DOTAP analogs, Biochim. et Biophysica Acta (BBA) – Biomembranes, 1464, 151, 10.1016/S0005-2736(00)00126-7 Zhang, 2010, DC-Chol/DOPE cationic liposomes: a comparative study of the influence factors on plasmid pDNA and siRNA gene delivery, Int. J. Pharm., 390, 198, 10.1016/j.ijpharm.2010.01.035 Muñoz-Úbeda, 2010, Effect of lipid composition on the structure and theoretical phase diagrams of DC-Chol/DOPE-DNA lipoplexes, Biomacromolecules, 11, 3332, 10.1021/bm1008124 Maitani, 2007, Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression, Int. J. Pharm., 342, 33, 10.1016/j.ijpharm.2007.04.035 Harvie, 2000, Use of Poly(ethylene glycol)–Lipid Conjugates to Regulate the Surface Attributes and Transfection Activity of Lipid–DNA Particles, J. Pharm. Sci., 89, 652, 10.1002/(SICI)1520-6017(200005)89:5<652::AID-JPS11>3.0.CO;2-H Takano, 2003, Physicochemical properties of liposomes affecting apoptosis induced by cationic liposomes in macrophages, Pharm. Res., 20, 962, 10.1023/A:1024441702398 A. Akinc, W. Querbes, S. De, J. Qin, M. Frank-Kamenetsky, K.N. Jayaprakash, M. Jayaraman, K.G. Rajeev, W.L. Cantley, J.R. Dorkin, J.S. Butler, L. Qin, T. Racie, A. Sprague, E. Fava, A. Zeigerer, M.J. Hope, M. Zerial, D.W.Y. Sah, K. Fitzgerald, M.A. Tracy, M. Manoharan, V. Koteliansky, A.d. Fougerolles, M.A. Maier, Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms, Molecular therapy : the journal of the American Society of Gene Therapy, 18 (2010) 1357–1364. Lutz, 2017, Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines, NPJ Vaccines, 2, 29, 10.1038/s41541-017-0032-6 Pardi, 2017, Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination, Nature, 543, 248, 10.1038/nature21428 Zhang, 2015, Effect of vaccine administration modality on immunogenicity and efficacy, Expert Rev. Vaccines, 14, 1509, 10.1586/14760584.2015.1081067 Tian, 2018, Formulation in DDA-MPLA-TDB Liposome Enhances the Immunogenicity and Protective Efficacy of a DNA Vaccine against Mycobacterium tuberculosis Infection, Front. Immunol., 9, 310, 10.3389/fimmu.2018.00310 Melo, 2019, Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles, Mol. Ther. : J. Am. Soc. Gene Ther., 27, 2080, 10.1016/j.ymthe.2019.08.007 Blakney, 2019, The skin you are in: design-of-experiments optimization of lipid nanoparticle self-amplifying RNA formulations in human skin explants, ACS Nano, 13, 5920, 10.1021/acsnano.9b01774 Pollard, 2013, Type I IFN counteracts the induction of antigen-specific immune responses by lipid-based delivery of mRNA vaccines, Molecular Ther. : J. Am. Soc. Gene Ther., 21, 251, 10.1038/mt.2012.202 Verbeke, 2017, Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA, J. Control. Release, 266, 287, 10.1016/j.jconrel.2017.09.041 Iavarone, 2017, Mechanism of action of mRNA-based vaccines, Expert Rev. Vaccines, 16, 871, 10.1080/14760584.2017.1355245 Pepini, 2017, Induction of an IFN-mediated antiviral response by a self-amplifying RNA vaccine: implications for vaccine design, J. Immunol., 198, 4012, 10.4049/jimmunol.1601877 Blakney, 2019, Inside out: optimization of lipid nanoparticle formulations for exterior complexation and in vivo delivery of saRNA, Gene Ther., 10.1038/s41434-019-0095-2 Liang, 2017, Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques, Mol. Ther., 25, 2635, 10.1016/j.ymthe.2017.08.006 Carstens, 2011, Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines, Vaccine, 29, 4761, 10.1016/j.vaccine.2011.04.081 Kaur, 2012, Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses, J. Controlled Release : Off. J. Controlled Release Soc., 158, 72, 10.1016/j.jconrel.2011.10.012 Lazzaro, 2015, CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes, Immunology, 146, 312, 10.1111/imm.12505 Roces, 2019, Scale-independent microfluidic production of cationic liposomal adjuvants and development of enhanced lymphatic targeting strategies, Mol. Pharm., 10.1021/acs.molpharmaceut.9b00730